Could your stomach meds be sabotaging cancer treatment?

NCT ID NCT07191171

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether certain drugs that change the gut bacteria (like antibiotics or acid reducers) can affect how well immunotherapy works in people with advanced lung cancer. Researchers will review medical records from 800 patients to see if those who took these drugs had different survival rates. The goal is to find ways to improve immunotherapy success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors choose which drugs to avoid alongside immunotherapy to improve lung cancer survival.

What could go wrong

This is a retrospective study, so it can only show links, not prove cause and effect. Results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSBIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dysbiosis lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Service de Pneumologie - CHU de Strasbourg - France

    RECRUITING

    Strasbourg, 67091, France

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact